Analysis – Page 67 – Goldea Capital

Vireo Growth Inc. Announces First Quarter 2026 Results

Written by Customer Service on May 12, 2026. Posted in Earnings Releases And Operating Results.

Q1 GAAP revenue of $106.2 million increased 333.5% year-over-year, driven by recently closed M&A transactions Moves to 4th largest cannabis company on a pro forma basis by revenue Closed the Schwazze acquisition and executed the PharmaCann MSA during the quarter Closed the Eaze and Hawthorne acquisitions subsequent to quarter end Announced a definitive agreement to acquire FLUENT and a joint venture with Glass House Brands subsequent to quarter end Company closed Q1 with $137.8 million in cash; expects to remain acquisitive MINNEAPOLIS, May 12, 2026 (GLOBE NEWSWIRE) — Vireo Growth Inc. (“Vireo” or the “Company”) (CSE: VREO; OTCQX: VREOF), today reported financial results for its first fiscal quarter ended March 31, 2026. Key financial results are presented below in summary form with supporting commentary and discussion...

Sylogist Announces First Quarter 2026 Results

Written by Customer Service on May 12, 2026. Posted in Earnings Releases And Operating Results.

Q1 2026 Highlights Revenue (in $ millions) SaaS Subscription Recurring TotalReported Y/Y growth Reported Y/Y growth Reported Y/Y growth$8.1 4.9% $11.1 1.1% $14.7 (9.7)% SaaS ARR up 7% Y/Y to $33.6 million; Total ARR up 3% Y/Y to $45.6 million; Gross Profit margin of 57%; Recurring Revenue at 75% of Total Revenue; Net Loss of $3.8 million; and Adjusted EBITDA1 margin of 7.9% or $1.2 millionCALGARY, Alberta, May 12, 2026 (GLOBE NEWSWIRE) — Sylogist Ltd. (TSX:SYZ) (“Sylogist” or the “Company”), a leading public sector SaaS company, today announced its financial results for the three months ended March 31, 2026. “The Company remains focused on completing the final steps in its transformation to a dynamic SaaS business model,” said Craig O’Neill, Interim President and CEO of Sylogist. “Following several years...

Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates

Written by Customer Service on May 12, 2026. Posted in Earnings Releases And Operating Results.

On track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Presented new preclinical data for XTX601, a potential first-in-class masked T cell engager targeting CLDN18.2, at the AACR annual meeting Advancing potential first-in-class multi-specific, masked T cell engager targeting PSMA and STEAP1 Achieved development milestone under AbbVie collaboration and extended cash runway into early 2028 WALTHAM, Mass., May 12, 2026 (GLOBE NEWSWIRE) — Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced pipeline progress and business updates and reported financial results for the first quarter ended March...

Harvard Bioscience Announces First Quarter 2026 Financial Results

Written by Customer Service on May 12, 2026. Posted in Earnings Releases And Operating Results.

First Quarter 2026 Revenues of $20.8M and Gross Margin of 59% Consolidation of Manufacturing Operations Progressing on Schedule Reaffirms Full Year 2026 Financial GuidanceHOLLISTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) — Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”) today announced financial results for the first quarter ended March 31, 2026. “First quarter revenues were in line with our expectations and gross margin expanded year-over-year, while we remained profitable on an adjusted EBITDA basis,” said John Duke, President and Chief Executive Officer. “We are encouraged by the adoption rates of our NPI portfolio – specifically the MeshMEA™ organoid platform, and our BTX® Electroporation and SoHo™ Telemetry systems – which are deepening our reach into the biopharma sector. This...

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

Written by Customer Service on May 12, 2026. Posted in Earnings Releases And Operating Results.

Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027 Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in established autoimmune type 1 diabetes Strong cash position, reflecting $95 million public offering proceeds, with operational runway through 2028 to support execution of SAFEGUARD and pre-commercial activities Conference call today at 8:30 AM ET MIAMI, May 12, 2026 (GLOBE NEWSWIRE) — SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced financial results for the first quarter...

Cal-Maine Foods and Sara Lee Frozen Bakery Announce Cal-Maine Foods’ Acquisition of Van’s Foods Brand, Advancing Cal-Maine Foods’ Diversification Strategy and Expanding Consumer-Facing Retail Presence

Written by Customer Service on May 12, 2026. Posted in Mergers And Acquisitions.

RIDGELAND, Miss, May 12, 2026 (GLOBE NEWSWIRE) — Cal-Maine Foods, Inc. (NASDAQ: CALM), the largest egg company in the United States and a leading player in the egg-based food industry, and Sara Lee Frozen Bakery, LLC, a leading manufacturer of premium frozen baked goods, today announced Cal-Maine Foods’ acquisition of certain assets of the Van’s Foods business of Sara Lee Frozen Bakery, LLC, a Kohlberg portfolio company. Van’s holds the top position in gluten-free waffles, establishing itself as a category leader within the fast-growing better-for-you frozen breakfast segment. This acquisition is aimed at supporting Cal-Maine Foods’ strategy to diversify its business model, grow in prepared foods business-to-consumer (B2C) retail, and deliver greater value across the supply chain. The addition of Van’s is expected to increase Cal-Maine...

Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights

Written by Customer Service on May 12, 2026. Posted in Earnings Releases And Operating Results.

Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026 Lead clinical candidate IND filing in Acumen’s EBDTM (enhanced brain delivery) program targeted for mid-2027 Cash, cash equivalents and marketable securities of $128.4 million as of Mar. 31, 2026, expected to support current clinical and operational activities into early 2027 Company to host conference call and webcast today at 8:00 a.m. ET NEWTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) — Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today reported financial results for...

George Weston Limited Reports First Quarter 2026 Results

Written by Customer Service on May 12, 2026. Posted in Earnings Releases And Operating Results.

TORONTO, May 12, 2026 (GLOBE NEWSWIRE) — George Weston Limited (TSX: WN) (“GWL” or the “Company”) today announced its consolidated unaudited results for the 12 weeks ended March 28, 2026(2). GWL’s 2026 First Quarter Report has been filed on SEDAR+ and is available at www.sedarplus.ca and in the Investor Centre section of the Company’s website at www.weston.ca. “George Weston delivered another quarter of strong financial results, reflecting consistent performance across our market leading businesses,” said Galen G. Weston, Chairman and Chief Executive Officer, George Weston Limited. “We are delighted to support Choice Properties with their transformational acquisition of First Capital assets, a deal that is completely in line with George Weston’s long term growth objectives.” Loblaw Companies Limited (“Loblaw”) delivered a...

C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

Written by Customer Service on May 12, 2026. Posted in Earnings Releases And Operating Results.

Progressed Plans to Establish Cemsidomide as a Potentially Foundational Treatment for Multiple Myeloma; Enrollment Ongoing in Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination with Elranatamab Additional Phase 1b Trial Evaluating Cemsidomide in Combination with Approved Multiple Myeloma Therapies Expected to Initiate in the First Half of 2027 Expanded Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader Antibody Conjugates Cash, Cash Equivalents and Marketable Securities of $268.3 Million as of March 31, 2026 with Cash Runway to the End of 2028 WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD)...

eToro Reports First Quarter 2026 Results

Written by Customer Service on May 12, 2026. Posted in Earnings Releases And Operating Results.

Net Contribution of $258 million, up 19% YoY Net Income of $82 Million, up 37% YoY Adjusted EBITDA of $109 million, up 35% YoY 4.02 million funded accounts, up 12% YoY NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) — eToro Group Ltd. (“eToro”, or the “Company”) (NASDAQ: ETOR), the trading and investing platform, today announced financial results for the first quarter ended March 31, 2026. “I’m incredibly proud of the eToro team for delivering our strongest quarterly financial results as a public company, while continuing to accelerate product innovation. In the first quarter, we introduced 24/7 trading for commodities, equities and indices, added Japanese equities, and launched crypto trading in New York. We also saw acceleration in product launches with many new apps within the eToro App Store, AI-powered Agent Portfolios, and an...

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals